Cover image for Vol. 120 Issue 23

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/203 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians


  1. 1 - 100
  2. 101 - 156
  1. Original Articles

    1. Disease Site

      Endocrine Disease
      Should small papillary thyroid cancer be observed? A population-based study

      Naris Nilubol and Electron Kebebew

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29123

      Nonoperative management should be used with caution for patients who have papillary thyroid cancers that measure ≤2 cm in greatest dimension. Patients aged ≥45 years with papillary thyroid cancers ≤2 cm should undergo thyroidectomy.

    2. Discipline

      Radiation Oncology
      A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer

      Penny Fang, Rosemarie Mick, Curtiland Deville, Stefan Both, Justin E. Bekelman, John P. Christodouleas, Thomas J. Guzzo, Zelig Tochner, Stephen M. Hahn and Neha Vapiwala

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29148

      In this patient-level, matched comparison of prospectively collected toxicity data on patietns with localized prostate carcinoma who received treated with contemporary IMRT and PBT techniques and similar dose-fractionation regimens, risks of acute and late GI and GU toxicities were not significantly different after careful adjustment for confounders and predictive factors.

  2. Erratum

    1. You have free access to this content
  3. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

      Frédéric Baron, Myriam Labopin, Andy Peniket, Pavel Jindra, Boris Afanasyev, Miguel A. Sanz, Eric Deconinck, Arnon Nagler and Mohamad Mohty

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29163

      Fludarabine and melphalan provide better acute myeloid leukemia control than fludarabine and busulfan as a reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation. Fludarabine plus busulfan and fludarabine plus melphalan provide similar overall survival.

    2. Discipline

      Metformin for primary colorectal cancer prevention in patients with diabetes: A case-control study in a US population

      Amikar Sehdev, Ya-Chen T. Shih, Benjamin Vekhter, Marc B. Bissonnette, Olufunmilayo I. Olopade and Blase N. Polite

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29165

      The use of metformin is associated with a reduced risk of developing colorectal cancer among patients with diabetes in the US population. Further studies are needed to understand the mechanism of action and the development of metformin for clinical use.

  4. Correspondence

  5. Erratum

    1. You have free access to this content

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29151

      This article corrects:
  6. Original Articles

    1. Discipline

      Outcomes Research
      Cognitive function and social attainment in adult survivors of retinoblastoma: A report from the St. Jude Lifetime Cohort Study

      Tara M. Brinkman, Thomas E. Merchant, Zhenghong Li, Rachel Brennan, Matthew Wilson, Mary Ellen Hoehn, Ibrahim Qaddoumi, Sean Phipps, Deokumar Srivastava, Leslie L. Robison, Melissa M. Hudson and Kevin R. Krull

      Article first published online: 24 NOV 2014 | DOI: 10.1002/cncr.28924

      Adult survivors of retinoblastoma demonstrate few cognitive or social attainment deficits decades following diagnosis and treatment. Findings suggest the potential for neural reorganization following early insult to the visual system, but further research is needed.

    2. Disease Site

      Genitourinary Disease
      Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

      Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William K. Kelly and Howard L. McLeod

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29169

      The authors demonstrate that bevacizumab treatment is significantly associated with arterial thromboembolism (ATE) only, and not with venous thromboembolism (VTE). In addition, results from this study indicate that increasing age is significantly associated with the risk of both ATE and VTE in patients with prostate cancer, whereas the VTE risk score, which incorporates leukocyte count, hemoglobin, platelet count, body mass index, and tumor location, is significantly associated with the risk of VTE.

    3. Hematologic Malignancies
      Perinatal and familial risk factors for acute lymphoblastic leukemia in a Swedish national cohort

      Casey Crump, Jan Sundquist, Weiva Sieh, Marilyn A. Winkleby and Kristina Sundquist

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29172

      The authors conducted what to their knowledge is the largest population-based cohort study to date to examine perinatal and familial risk factors for acute lymphoblastic leukemia (ALL) among approximately 3.5 million individuals born in Sweden between 1973 and 2008. High fetal growth was found to be associated with an increased risk of ALL in childhood through young adulthood, independent of gestational age at birth, suggesting that growth factor pathways may play an important long-term role in the etiology of ALL.

  7. Editorials

    1. Bevicizumab and thrombosis: Some answers but questions remain

      Thomas G. DeLoughery and Tomasz M. Beer

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29168

      The study by Patel and colleagues reported in this issue verifies the increased risk of arterial thrombosis, but not venous thrombosis, with the receipt of bevacizumab. The focus of future research now needs to be on ameliorating this increased risk and identifying the mechanism for prothrombotic effects of targeted antineoplastic therapy.

  8. Original Articles

    1. Discipline

      Clinical Trials
      You have full text access to this OnlineOpen article
      Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors

      Johanna C. Bendell, Manish R. Patel, Jeffrey R. Infante, Carla D. Kurkjian, Suzanne F. Jones, Shubham Pant, Howard A. Burris III, Ofir Moreno, Vanessa Esquibel, Wendy Levin and Kathleen N. Moore

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29155

      The current phase 1, open-label, dose escalating, first-in human study of ME-344 in patients with refractory solid tumors found that the maximum tolerated dose of once-weekly 10-mg/kg administration of the drug was generally well tolerated. The preliminary clinical activity as a monotherapy supports the further clinical development of ME-344 in combination with chemotherapy.

    2. Epidemiology
      Quality of life over 5 years after a breast cancer diagnosis among low-income women: Effects of race/ethnicity and patient-physician communication

      Rose C. Maly, Yihang Liu, Li-Jung Liang and Patricia A. Ganz

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29150

      The current study is among the first and largest studies to examine risk factors for poorer quality of life among newly diagnosed, low-income women with breast cancer over time. The results suggest that quality of life in this vulnerable population could be particularly improved by targeted interventions aimed at increasing physician information-giving and empowering patients in communicating with physicians, as well as by attention to comorbid medical conditions.

    3. Disease Site

      Genitourinary Disease
      Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

      Daniel A. Hamstra, Kyounghwa Bae, Gerald Hanks, Chen Hu, William U. Shipley, Charlie C. Pan, Mack Roach III, Colleen A. Lawton and Howard M. Sandler

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29146

      After radiation therapy, biochemical failure is defined on the basis of either rising prostate-specific antigen levels or the initiation of salvage androgen ablation for other reasons. Patients started on salvage androgen therapy without meeting the criteria for rising prostate-specific antigen levels may have worse clinical outcomes; as such, those with rising prostate-specific antigen levels only may actually represent a more favorable group of patients.

    4. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer

      Hung-Jui Tan, Anne-Marie Meyer, Tzy-Mey Kuo, Angela B. Smith, Stephanie B. Wheeler, William R. Carpenter and Matthew E. Nielsen

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29144

      Provider-based research networks such as the Community Clinical Oncology Program offer a potential conduit for the diffusion of technology into the treatment of patients with cancer. However, the utilization of laparoscopy and partial nephrectomy for kidney cancer did not differ according to the Community Clinical Oncology Program affiliation status, and this indicates potential limits of provider-based research networks in translating evidence-based cancer care into clinical practice.

    5. Hematologic Malignancies
      Outcome of Patients With Low-Risk and Intermediate-1—Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure: A Report on Behalf of the MDS Clinical Research Consortium

      Elias J. Jabbour, Guillermo Garcia-Manero, Paolo Strati, Asmita Mishra, Najla H. Al Ali, Eric Padron, Jeffrey Lancet, Tapan Kadia, Naval Daver, Susan O'Brien, David P. Steensma, Mikkael A. Sekeres, Steven D. Gore, Amy Dezern, Gail J. Roboz, Alan F. List, Hagop M. Kantarjian and Rami S. Komrokji

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29145

      The outcomes of patients with lower-risk myelodysplastic syndromes after treatment failure with hypomethylating agents are poor, with a median survival of 17 months reported. Overall survival is a reasonable primary endpoint for clinical studies targeting this patient population.

  9. Editorials

    1. Struggles in exporting complex surgical advances

      Christopher Weight

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29143

      The diffusion of complex surgical innovations is challenging and slow and, in some cases, may not be in the patient's best interest. Perhaps better patient education and empowerment will allow the best care at lower cost.

  10. Original Articles

    1. Discipline

      Disparities Research
      Video-based educational tool improves patient comprehension of common prostate health terminology

      Daniel S. Wang, Ashesh B. Jani, Musu Sesay, Caroline G. Tai, Daniel K. Lee, Katharina V. Echt, Michael G. Goodman, Kerry E. Kilbridge and Viraj A. Master

      Article first published online: 12 NOV 2014 | DOI: 10.1002/cncr.29101

      Recent studies have revealed a disheartening lack of comprehension of medical terms often used in counseling patients about treatment options. To address this vital component of shared decision making, a video-based educational tool has been developed, and it results in significant gains in patient comprehension of such terminology.

    2. Disease Site

      Hematologic Malignancies
      Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?

      Fuad El Rassi, John D. Bergsagel, Martha Arellano, Manila Gaddh, Anand Jillella, Vamsi Kota, Leonard T. Heffner, Elliott F. Winton and Hanna Jean Khoury

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29142

      Flow cytometry (FC) is a commonly requested test in the workup of leukocytosis in community practices, and the role of FC in chronic-phase chronic myeloid leukemia (CP-CML) is unknown. In contrast to the detection of aberrant myeloid markers, the detection of lymphoid markers by FC at the time of the diagnosis of CP-CML appears to be associated with early progression to the lymphoid blast phase.

    3. Soft Tissue and Bone Sarcoma
      Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survival

      Jason U. Tilan, Mark Krailo, Donald A. Barkauskas, Susana Galli, Haifa Mtaweh, Jessica Long, Hongkun Wang, Kirsten Hawkins, Congyi Lu, Dima Jeha, Ewa Izycka-Swieszewska, Elizabeth R. Lawlor, Jeffrey A. Toretsky and Joanna B. Kitlinska

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29090

      Elevated systemic levels of neuropeptide Y, an EWS-FLI1 transcriptional target that is highly expressed in Ewing sarcoma, are associated with unfavorable clinical features, such as pelvic localization, the presence of metastases, and bone origin. Conversely, high activity of dipeptidyl peptidase IV in patients' sera is associated with a better prognosis, suggesting a potential role for the protease in antitumor immune response.

    4. Discipline

      Complementary Medicine
      Cancer survivors' disclosure of complementary health approaches to physicians: The role of patient-centered communication

      Stephanie J. Sohl, Laurel A. Borowski, Erin E. Kent, Ashley Wilder Smith, Ingrid Oakley-Girvan, Russell L. Rothman and Neeraj K. Arora

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29138

      Analyses of a population-based sample of cancer survivors support the idea that improving the overall patient centeredness of cancer follow-up care and improving the disclosure of complementary health approaches to physicians are potentially synergistic clinical goals.

    5. Disease Site

      Hematologic Malignancies
      Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

      Avichai Shimoni, Yulia Volchek, Maya Koren-Michowitz, Nira Varda-Bloom, Raz Somech, Noga Shem-Tov, Ronit Yerushalmi and Arnon Nagler

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29141

      Nilotinib is relatively safe and effective as prophylactic therapy for the prevention of relapse after allogeneic stem cell transplantation in the setting of advanced chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia.

  11. Erratum

    1. You have free access to this content
  12. Original Articles

    1. Disease Site

      Genitourinary Disease
      Knowledge of the harms of tobacco use among patients with bladder cancer

      Jeffrey C. Bassett, John L. Gore, Lorna Kwan, Chad R. Ritch, Daniel A. Barocas, David F. Penson, William J. McCarthy and Christopher S. Saigal

      Article first published online: 10 NOV 2014 | DOI: 10.1002/cncr.28915

      The full impact of the diagnosis of a tobacco-related malignancy on subsequent tobacco use requires patient knowledge of association. Our study demonstrates the pivotal role of the urologist in ensuring smokers diagnosed with bladder cancer are aware of the bladder-specific harms of their tobacco use.

    2. Hematologic Malignancies
      Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

      Meagan S. Barbee, Ajay Nooka, Jonathan L. Kaufman, Sungjin Kim, Zhengjia Chen, Leonard T. Heffner Jr, Sagar Lonial and R. Donald Harvey

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29136

      The findings of this study validate the use of the International Myeloma Working Group criteria in a phase 1 setting but bring into question the boundaries of response set forth by the criteria in a phase 1 population. It is suggested that normalization of the free light chain ratio be considered in future phase 1 studies as an early indicator of response to promote rapidity in moving novel therapies and combinations into the phase 2 evaluation.

    3. Discipline

      Clinical Trials
      Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

      Robert C. Doebele, David Spigel, Mustapha Tehfe, Sachdev Thomas, Martin Reck, Sunil Verma, Janice Eakle, Frederique Bustin, Jerome Goldschmidt Jr, Dachuang Cao, Ekaterine Alexandris, Sergey Yurasov, D. Ross Camidge and Philip Bonomi

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29132

      Although a statistically significant improvement in progression-free survival is not achieved in this phase 2 randomized study, ramucirumab shows evidence of clinical activity in combination with pemetrexed-platinum chemotherapy in patients with nonsquamous non–small cell lung cancer. The addition of ramucirumab does not result in new or unexpected safety findings.

    4. Disparities Research
      A mixed-methods examination of communication between oncologists and primary care providers among primary care physicians in underserved communities

      Megan Johnson Shen, Maria Binz-Scharf, Tom D'Agostino, Natasha Blakeney, Elisa Weiss, Margo Michaels, Shilpa Patel, M. Diane McKee and Carma L. Bylund

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29131

      Primary care physicians (PCPs) treating underserved, minority patients want to be more involved in patient care during and after cancer treatment, but significant communication gaps occur between oncologists and PCPs during this time. A focus on improving PCP-oncologist communication during treatment could reduce the burden on oncologists and improve patient satisfaction and care, specifically among underserved, minority populations.

    5. Epidemiology
      The rise in metastasectomy across cancer types over the past decade

      Edmund K. Bartlett, Kristina D. Simmons, Heather Wachtel, Robert E. Roses, Douglas L. Fraker, Rachel R. Kelz and Giorgos C. Karakousis

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29134

      From 2000 through 2011, metastasectomy was increasingly performed for patients with colorectal cancer, lung cancer, breast cancer, and melanoma. Inpatient mortality decreased despite increasing patient comorbidity. The increased performance of metastasectomy was predominately driven by high-volume institutions.

    6. Disease Site

      Soft Tissue and Bone Sarcoma
      Significant association between human osteosarcoma and simian virus 40

      Elisa Mazzoni, Maria Serena Benassi, Alfredo Corallini, Giovanni Barbanti-Brodano, Angelo Taronna, Piero Picci, Giovanni Guerra, Antonio D'Agostino, Lorenzo Trevisiol, Pier Francesco Nocini, Maria Vittoria Casali, Giuseppe Barbanti-Brodano, Fernanda Martini and Mauro Tognon

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29137

      Patients with osteosarcoma carry at high prevalence of simian virus 40 antibodies. The results of the current study indicate that these patients could be treated with antivirals.

    7. Discipline

      Psychosocial Oncology
      Experiencing reproductive concerns as a female cancer survivor is associated with depression

      Jessica R. Gorman, H. Irene Su, Samantha C. Roberts, Sally A. Dominick and Vanessa L. Malcarne

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29133

      Addressing the reproductive concerns experienced by young adult female cancer survivors is an important element of comprehensive survivorship care and has the potential to improve psychosocial health.

    8. Epidemiology
      Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: A study of the Veterans Affairs health care system

      Jose P. Zevallos, Christine M. Hartman, Jennifer R. Kramer, Erich M. Sturgis and Elizabeth Y. Chiao

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29122

      Although the incidence of thyroid cancer has doubled within the Veterans Affairs health care system, a nearly 5-fold increase in the use of thyroid ultrasound and a nearly 7-fold increase in the use of fine-needle aspiration occurred between 2000 and 2012. These findings suggest that the increase in thyroid cancer incidence may be related to increases in the use of ultrasound and fine-needle aspiration.

    9. Outcomes Research
      Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system–directed therapy

      Cara I. Kimberg, James L. Klosky, Nan Zhang, Tara M. Brinkman, Kirsten K. Ness, Deo Kumar Srivastava, Leslie L. Robison, Melissa M. Hudson and Kevin R. Krull

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29121

      Survivors of childhood cancer treated with central nervous system–directed therapy are at risk for poor health care utilization in part because of reduced global cognition. Educational approaches regarding recommended health care should be modified to ensure comprehension by survivors with neurocognitive impairment.

    10. Disease Site

      Gastrointestinal Disease
      Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?

      Timothy J. Price, Carol Beeke, Shahid Ullah, Robert Padbury, Guy Maddern, David Roder, Amanda R. Townsend, James Moore, Amitesh Roy, Yoko Tomita and Christos Karapetis

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29129

      The primary site of metastatic colorectal cancer impacts survival outcomes. Stratification by left and right colon should be considered in trial design.

    11. Discipline

      Outcomes Research
      Critical evaluation of the scientific content in clinical practice guidelines

      Zaid M. Abdelsattar, Bradley N. Reames, Scott E. Regenbogen, Samantha Hendren and Sandra L. Wong

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29124

      There is significant variation in the development processes and scientific content of clinical practice guidelines. Differences in interpreting the evidence and conflicting recommendations call for improving the quality and consistency of guidelines.

    12. Quality of Life
      Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: A population-based, case-control study

      Caroleen Quach, Hanna K. Sanoff, Grant R. Williams, Jessica C. Lyons and Bryce B. Reeve

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29125

      Older Americans with colorectal cancer, particularly later-stage patients, experience significant decrements in physical and mental health aspects of health-related quality of life, including activities of daily living impairment and being at greater risk for major depressive disorder, following diagnosis and treatment compared to matched noncancer controls.

    13. Psychosocial Oncology
      Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care

      Lynne I. Wagner, Julian Schink, Michael Bass, Shalini Patel, Maria Varela Diaz, Nan Rothrock, Timothy Pearman, Richard Gershon, Frank J. Penedo, Steven Rosen and David Cella

      Article first published online: 6 NOV 2014 | DOI: 10.1002/cncr.29104

      The successful implementation of an electronic patient-reported outcome (ePRO) system using the Patient Reported Outcomes Measurement Information System is demonstrated for the precise, valid, and robust measurement of common cancer-related symptoms with electronic health record integration for immediate clinician notification and with triage for identified problems. Six hundred thirty-six gynecologic oncology outpatients complete the ePRO assessment, and they demonstrate its feasibility and provide information on the most common symptom-related and psychosocial concerns.

  13. Editorials

    1. Inherited predisposition to endometrial cancer: Moving beyond Lynch syndrome

      Zsofia K. Stadler and Mark E. Robson

      Article first published online: 5 NOV 2014 | DOI: 10.1002/cncr.29107

      A number of predisposition syndromes include endometrial cancer as a component tumor. These can generally be identified on the basis of the family history and the individual phenotype.

  14. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with cowden and cowden-like syndromes: An international, multicenter, prospective study

      Haider Mahdi, Jessica L. Mester, Emily A. Nizialek, Joanne Ngeow, Chad Michener and Charis Eng

      Article first published online: 5 NOV 2014 | DOI: 10.1002/cncr.29106

      In this prospective study of endometrial cancer patients with the Cowden phenotype, clinical predictors of a germline phosphatase and tensin homolog (PTEN) mutation include a younger age, macrocephaly, a high Cleveland Clinic score, a low PTEN protein level, and coexisting renal cancer. Endometrial cancer patients with germline KLLN promoter methylation are likely to have an increased phenotypic load and to present at younger ages similarly to those with a germline PTEN mutation. Thus, high-risk cancer surveillance and prophylactic surgery of the uterus may be considered for these patients similarly to those with PTEN mutations.

    2. Discipline

      Outcomes Research
      Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage

      Erin E. Kent, Anita Ambs, Sandra A. Mitchell, Steven B. Clauser, Ashley Wilder Smith and Ron D. Hays

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29119

      The health-related quality of life of older adult survivors of less common cancers is compared to the health-related quality of life of older individuals with no cancer history on the basis of data from the Surveillance, Epidemiology, and End Results/Medicare Health Outcomes Survey linked data resource. Inferior health-related quality of life (particularly impaired physical health) is found among survivors of several cancer types; the greatest deficits are reported by those with multiple myeloma and pancreatic cancer.

    3. The symptom burden of treatment-naive patients with head and neck cancer

      Ehab Y. Hanna, Tito R. Mendoza, David I. Rosenthal, G. Brandon Gunn, Pamela Sehra, Emre Yucel and Charles S. Cleeland

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29097

      Moderate to severe symptoms were found to be highly prevalent in the current study of treatment-naive patients with head and neck cancer, thereby demonstrating the importance of pretreatment symptom assessment and the need for symptom management together with disease treatment. Knowledge of disease-related (treatment-naive) symptom status is critical for evaluating the symptomatic benefit/burden of therapies for head and neck cancer.

    4. Disease Site

      Soft Tissue and Bone Sarcoma
      Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors

      Roger T. Anderson, Cyllene R. Morris, Gretchen Kimmick, Amy Trentham-Dietz, Fabian Camacho, Xiao-Cheng Wu, Susan A. Sabatino, Steven T. Fleming and Joseph Lipscomb

      Article first published online: 4 NOV 2014 | DOI: 10.1002/cncr.29092

      In a large national database, the likelihood of receiving guideline-concordant care among patients with nonmetastatic breast cancer is lower with older age and with public insurance versus private insurance. Radiation therapy is the most omitted treatment component. Patient navigation targeted at high-risk or vulnerable patients may be needed to ensure access to high-quality care.

    5. Discipline

      Psychosocial Oncology
      You have full text access to this OnlineOpen article
      Mindfulness-based cancer recovery and supportive-expressive therapy maintain telomere length relative to controls in distressed breast cancer survivors

      Linda E. Carlson, Tara L. Beattie, Janine Giese-Davis, Peter Faris, Rie Tamagawa, Laura J. Fick, Erin S. Degelman and Michael Speca

      Article first published online: 3 NOV 2014 | DOI: 10.1002/cncr.29063

      Psychosocial interventions providing stress reduction and emotional support resulted in a trend toward telomere length maintenance in distressed breast cancer survivors compared with decreases in usual care. To the authors' knowledge, this is the first study to investigate the potential for short-term interventions to affect this important biomarker, but the clinical implications of the finding require further exploration.

  15. Review Articles

    1. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors

      Smita Bhatia

      Article first published online: 29 OCT 2014 | DOI: 10.1002/cncr.29096

      Treatment-related second cancers are a major cause of morbidity in cancer survivors. This review describes the current state of knowledge regarding the role of genetic susceptibility in the development of treatment-related second cancers.

    2. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

      Curtis R. Pickering, Robert C. Bast Jr and Khandan Keyomarsi

      Article first published online: 29 OCT 2014 | DOI: 10.1002/cncr.29033

      Medical advances happen only as a result of successful translational research endeavors, which are built on a foundation of basic science. Investigators with a deep understanding of fundamental biology and the mechanisms of disease are essential for translating laboratory discoveries into new and improved health interventions, diagnostics, and treatments. A failure to support basic scientists in translational research will slow the progress of modern medical advances.

  16. Original Articles

    1. Discipline

      Clinical Trials
      Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma

      Ethan Toumishey, Angeli Prasad, Greg Dueck, Neil Chua, Daygen Finch, James Johnston, Richard van der Jagt, Doug Stewart, Darrell White, Andrew Belch and Tony Reiman

      Article first published online: 29 OCT 2014 | DOI: 10.1002/cncr.29103

      Lenalidomide monotherapy demonstrates clinically relevant activity in patients with T-cell lymphoma and has a good safety profile. Lenalidomide has excellent potential as an agent in combination therapy for patients with T-cell lymphoma.

    2. Pathology
      Analysis of thyroid malignant pathologic findings identified during 3 rounds of screening (1997-2008) of a cohort of children and adolescents from belarus exposed to radioiodines after the Chernobyl accident

      Lydia B. Zablotska, Eldar A. Nadyrov, Alexander V. Rozhko, Zhihong Gong, Olga N. Polyanskaya, Robert J. McConnell, Patrick O'Kane, Alina V. Brenner, Mark P Little, Evgenia Ostroumova, Andre Bouville, Vladimir Drozdovitch, Viktor Minenko, Yuri Demidchik, Alexander Nerovnya, Vassilina Yauseyenka, Irina Savasteeva, Sergey Nikonovich, Kiyohiko Mabuchi and Maureen Hatch

      Article first published online: 28 OCT 2014 | DOI: 10.1002/cncr.29073

      In the largest series of thyroid cancers identified through systematic screening of children and adolescents from Belarus who were exposed to radioactive iodine from fallout after the Chernobyl accident in 1986, radiation doses to the thyroid gland are associated with histopathologic features of tumor aggressiveness, a higher probability of multifocal cancers, and a higher probability of solid and diffuse sclerosing variants of thyroid cancer pathology.

  17. Editorial

    1. Systematic screening after Chernobyl: Insights on radiation-induced thyroid cancer

      Linwah Yip and Sally E. Carty

      Article first published online: 28 OCT 2014 | DOI: 10.1002/cncr.29074

      Radiation-induced thyroid cancer remains an important public health issue after the Chernobyl accident. A systematic screening of the at-risk population provides new insights into the dose-dependent and time-dependent histologic features of the diagnosed thyroid cancers.

  18. Review Articles

    1. Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?

      Elisavet Paplomata, Rita Nahta and Ruth M. O'Regan

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29060

      Patients with small human epidermal growth factor receptor 2 (HER2)-positive cancers have an excellent outcome when treated with trastuzumab-based chemotherapy, suggesting that less aggressive treatment approaches may be appropriate for some patients. HER2-positive cancers that coexpress hormone receptors are heterogenous, and a subset appear to be driven at least in part by estrogen receptor and may be optimally treated with coinhibition of estrogen receptor and HER2 rather than chemotherapy.

  19. Original Articles

    1. Discipline

      Translational Research
      Clinical next-generation sequencing in patients with non–small cell lung cancer

      Ian S. Hagemann, Siddhartha Devarakonda, Christina M. Lockwood, David H. Spencer, Kalin Guebert, Andrew J. Bredemeyer, Hussam Al-Kateb, TuDung T. Nguyen, Eric J. Duncavage, Catherine E. Cottrell, Shashikant Kulkarni, Rakesh Nagarajan, Karen Seibert, Maria Baggstrom, Saiama N. Waqar, John D. Pfeifer, Daniel Morgensztern and Ramaswamy Govindan

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29089

      In a series of 381 consecutive non–small cell lung cancers submitted for clinical targeted next-generation sequencing, sequencing was successfully completed in 209 (55%) and resulted in the adoption of a targeted therapy in 22 (11%).

  20. Commentary

    1. Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules

      Joëlle Guilhot, Claude Preudhomme, Francois Xavier Mahon and François Guilhot

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29053

      Clinical trials for chronic myeloid leukemia frequently rely on molecular response as an outcome measurement. Unfortunately, as a surrogate marker, molecular response brings with it limitations related to both laboratory techniques as well as disease parameters.

  21. Original Articles

    1. Disease Site

      Genitourinary Disease
      Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility

      Phillip J. Gray, Chun Chieh Lin, Helmneh Sineshaw, Jonathan J. Paly, Ahmedin Jemal and Jason A. Efstathiou

      Article first published online: 24 OCT 2014 | DOI: 10.1002/cncr.29094

      In an analysis of 34,067 patients with stage I testicular seminoma, the rate of observation after orchiectomy increases from 23.7% in 1998 to 54.0% in 2011. Racial minorities, the uninsured, and those treated at academic centers are more likely to receive observation.

  22. Editorials

  23. Original Articles

    1. Discipline

      Pediatric Oncology
      Cancer-related follow-up care among hispanic and non-Hispanic childhood cancer survivors: The project forward study

      Joel E. Milam, Kathleen Meeske, Rhona I. Slaughter, Sandra Sherman-Bien, Anamara Ritt-Olson, Aura Kuperberg, David R. Freyer and Ann S. Hamilton

      Article first published online: 23 OCT 2014 | DOI: 10.1002/cncr.29105

      Follow-up care is critical for childhood cancer survivors who are at high risk for comorbidities and late effects of cancer treatments. Among 193 recently treated childhood cancer survivors, those who were Hispanic, older, or missing health insurance were at higher risk for lacking cancer follow-up care.

    2. Psychosocial Oncology
      Association between serious psychological distress and health care use and expenditures by cancer history

      Xuesong Han, Chun Chieh Lin, Chunyu Li, Janet S. de Moor, Juan L. Rodriguez, Erin E. Kent and Laura P. Forsythe

      Article first published online: 23 OCT 2014 | DOI: 10.1002/cncr.29102

      Serious psychological distress is reported to be associated with adverse health outcomes such as poor quality of life and shorter survival in cancer survivors. In a national representative sample of cancer survivors, serious psychological distress was found to be associated with higher health care use and medical expenditures.

  24. Editorial

    1. Revisiting structure, process, and outcome

      Scott M. Gilbert

      Article first published online: 22 OCT 2014 | DOI: 10.1002/cncr.29070

      The quality of bladder cancer varies markedly, and bladder cancer has not garnered national attention despite the incidence and cost burden associated with bladder cancer. This editorial argues for revisiting Donabedian's structure, process, and outcome framework for quality assessment among patients with bladder cancer.

  25. Original Articles

    1. Disease Site

      Genitourinary Disease
      Quality of diagnostic staging in patients with bladder cancer: A process-outcomes link

      Karim Chamie, Eric Ballon-Landa, Jeffrey C. Bassett, Timothy J. Daskivich, Meryl Leventhal, Dennis Deapen and Mark S. Litwin

      Article first published online: 22 OCT 2014 | DOI: 10.1002/cncr.29071

      The medical records of 1865 patients with bladder cancer in Los Angeles County are reviewed, and suboptimal staging in nearly half of all diagnostic resections is found to be associated with increased mortality, particularly in patients with high-grade disease.

    2. Head and Neck Disease
      Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status

      Shao Hui Huang, John N. Waldron, Michael Milosevic, Xiaowei Shen, Jolie Ringash, Jie Su, Li Tong, Bayardo Perez-Ordonez, Ilan Weinreb, Andrew J. Bayley, John Kim, Andrew Hope, B.C. John Cho, Meredith Giuliani, Albiruni Razak, David Goldstein, Willa Shi, Fei-Fei Liu, Wei Xu and Brian O'Sullivan

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29100

      This relatively large cohort study reports an intriguing hypothesis-generating observation: high pretreatment neutrophil counts, high pretreatment monocyte counts, and low pretreatment lymphocyte counts independently predict inferior survival and disease control for human papillomavirus–positive oropharyngeal cancer patients, whereas a predictive value for human papillomavirus–negative patients is not apparent.

  26. Review Articles

    1. Small cell lung cancer: Where do we go from here?

      Lauren Averett Byers and Charles M. Rudin

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29098

      The treatment of small cell lung cancer has not changed significantly in 3 decades. In this review, the authors discuss the current challenges and opportunities to accelerate progress in this highly lethal disease.

    2. Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

      Ursula A. Matulonis, Amit M. Oza, Tony W. Ho and Jonathan A. Ledermann

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29082

      Overall survival is regarded as the most clinically relevant endpoint in trials of ovarian cancer, but it may be confounded by multiple lines of subsequent therapy. A primary endpoint of progression-free survival supported by intermediate clinical endpoints and overall survival provides a more comprehensive approach for evaluating efficacy.

  27. Editorials

    1. Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

      Janet E. Dancey

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29084

      Intermediate endpoints that better capture the benefits of treatment and patient outcomes will facilitate trial conduct and ultimately treatment decisions for individual patients. Whether the current crop of newer endpoints will improve trial conduct and the interpretation of outcomes will require further evaluation.

  28. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

      Jean-Pierre Issa, Guillermo Garcia-Manero, Xuelin Huang, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce and Hagop M. Kantarjian

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29085

      For this randomized study, a Bayesian design is used to compare decitabine with decitabine plus valproic acid in patients with myelodysplastic syndrome and in elderly patients with acute myelogenous leukemia. No benefit is demonstrated from the addition of valproic acid; and the toxicity of the combination—particularly neurotoxicity—is more significant.

  29. Editorials

    1. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges

      Michael Lübbert and Andrea Kuendgen

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29083

      In the first randomized trial of older patients with myelodysplastic syndrome/acute myeloid leukemia (adaptive randomization) to receive treatment with intravenous decitabine (5-day schedule) either alone or in combination with the oral histone deacetylase (HDAC) inhibitor valproic acid (7-day schedule), Issa and colleagues do not detect an improved response rate or overall survival with the combined treatment. The various factors potentially affecting clinical outcome in studies combining decitabine or 5-azacytidine with valproic acid or other HDAC inhibitors are discussed.

  30. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer

      Aalok Kumar, Hagen F. Kennecke, Daniel J. Renouf, Howard J. Lim, Sharlene Gill, Ryan Woods, Caroline Speers and Winson Y. Cheung

      Article first published online: 20 OCT 2014 | DOI: 10.1002/cncr.29072

      Stage II colon cancer has a relatively good prognosis. Patients who have high-risk disease based on clinical and pathological factors may derive benefit from adjuvant chemotherapy in the setting of specific high-risk features such as T4 disease.

    2. Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

      Sant P. Chawla, Victoria S. Chua, Andrew F. Hendifar, Doris V. Quon, Neelesh Soman, Kamalesh K. Sankhala, D. Scott Wieland and Daniel J. Levitt

      Article first published online: 13 OCT 2014 | DOI: 10.1002/cncr.29081

      At the maximum tolerated dose of 350 mg/m2, aldoxorubicin demonstrates clinical activity in patients with recurrent or refractory advanced solid tumors, including soft tissue sarcomas, without evidence of acute cardiotoxicity, which is a major limitation to the use of native doxorubicin. Aldoxorubicin may allow for higher dose equivalents of doxorubicin to be administered.

    3. Discipline

      Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes

      Julie Hallet, Calvin How Lim Law, Moises Cukier, Refik Saskin, Ning Liu and Simron Singh

      Article first published online: 13 OCT 2014 | DOI: 10.1002/cncr.29099

      Although the incidence of all neuroendocrine tumors has markedly increased over the course of 15 years, the proportion of metastatic disease at presentation has decreased, and this points toward increased detection outlining a rise in incidence. Socioeconomic status and rural residency portend worse survival for patients with neuroendocrine tumors, and they should be paid particular attention when initiatives are being designed to improve care for patients with neuroendocrine tumors.

    4. Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohort

      Won Jin Ho, Michael S. Simon, Vedat O. Yildiz, James M. Shikany, Ikuko Kato, Jennifer L. Beebe-Dimmer, Jeremy P. Cetnar and Cathryn H. Bock

      Article first published online: 9 OCT 2014 | DOI: 10.1002/cncr.29091

      Increased lycopene intake among postmenopausal women is associated with a lower risk of renal cell carcinoma in the Women's Health Initiative cohort. Further investigation into the correlation between lycopene intake and the risk of renal cell carcinoma is warranted.

  31. Commentary

    1. Eliminating cost-sharing requirements for colon cancer screening in Medicare

      David H. Howard, Gery P. Guy Jr and Donatus U. Ekwueme

      Article first published online: 9 OCT 2014 | DOI: 10.1002/cncr.29093

      Medicare beneficiaries incur out-of-pocket costs for polypectomies and colonoscopies after a positive fecal occult blood test. We estimate Medicare spending will increase by $48 million annually if Medicare waives cost-sharing requirements for these services.

  32. Original Articles

    1. Discipline

      Radiation Oncology
      A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy

      Jeremy Setton, Nancy Y. Lee, Nadeem Riaz, Shao-Hui Huang, John Waldron, Brian O'Sullivan, Zhigang Zhang, Weij Shi, David I. Rosenthal, Katherine A. Hutcheson and Adam S. Garden

      Article first published online: 6 OCT 2014 | DOI: 10.1002/cncr.29022

      In a multi-institution study of severe swallowing dysfunction requiring enteral support, patients are identified who previously received intensity-modulated radiotherapy with or without systemic therapy for oropharyngeal cancer. The results indicate that modern nonsurgical therapy for oropharyngeal cancer is associated with a low rate of long-term gastrostomy tube dependence.

  33. Review Articles

    1. Imaging of the axilla before preoperative chemotherapy: Implications for postmastectomy radiation

      Jose G. Bazan and Julia White

      Article first published online: 6 OCT 2014 | DOI: 10.1002/cncr.28859

      The decision to use postmastectomy radiotherapy for patients with breast cancer who receive neoadjuvant chemotherapy (NAC) is determined by the clinical extent of disease at presentation before NAC, the presence of pathologic residual disease (especially pathologically involved lymph nodes) after NAC, and the disease response to NAC. Therefore, accurate knowledge of the extent of axillary disease before NAC and assessment of response to therapy are critically important.

  34. Original Articles

    1. Disease Site

      Head and Neck Disease
      Prevalence and prognostic value of human papillomavirus genotypes in tonsillar squamous cell carcinoma: A Korean multicenter study

      Jae Hong No, Myung-Whun Sung, J. Hun Hah, Seung Ho Choi, Myung-Chul Lee, Hee Seung Kim and Yong-Sang Song

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29086

      The proportion of human papillomavirus–positive tonsillar cancer has increased during the last 20 years in Korea. The presence of human papillomavirus 18 may serve as a biomarker for a poor prognosis.

    2. Hematologic Malignancies
      Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

      Mohamad Mohty, Florent Malard, Didier Blaise, Noel Milpied, Sabine Furst, Resa Tabrizi, Thierry Guillaume, Stéphane Vigouroux, Jean El-Cheikh, Jacques Delaunay, Steven Le Gouill, Philippe Moreau, Myriam Labopin and Patrice Chevallier

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29087

      The reduced toxicity regimen based on a busulfan dose of 130 mg/m2/day intravenously for 3 days, fludarabine at a dose of 30 mg/m2/day for 5 days, and antithymocyte globulins at a dose of 2.5 mg/kg/day for 2 days was evaluated in a prospective phase 2 trial. This regimen appeared to be safe, with a low nonrecurrence mortality rate at 2 years in high-risk patients, and efficient disease control, thereby warranting prospective phase 3 trials.

    3. Discipline

      Outcomes Research
      Smoking history predicts for increased risk of second primary lung cancer: A comprehensive analysis

      John M. Boyle, Daniel J. Tandberg, Junzo P. Chino, Thomas A. D'Amico, Neal E. Ready and Chris R. Kelsey

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29095

      The current study identifies and quantifies risk factors for second primary lung cancer in a population of patients treated for an index non-small cell lung cancer. Among 1484 subjects, it was found that smoking was the only risk factor assessed that predicted for the development of a second primary lung cancer, with never-smokers having an exceedingly low risk.

  35. Editorials

    1. Targeted survival improvements in clinical trials: Are you an absolutist or relativist?

      James Paul

      Article first published online: 2 OCT 2014 | DOI: 10.1002/cncr.29031

      In this issue of Cancer, Castonguay et al highlights problems with reliably estimating the median OS in the control arm of clinical trials in ovarian cancer. This suggests that more careful reflection is genrally required concerning how clinically relevant differences are determined and highlights further issues with the selection of overall survival as a primary endpoint. The article also raises questions regarding the prevalent standard statistical approach used to design and analyze studies with time to event outcomes.

  36. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

      Vincent Castonguay, Michelle K. Wilson, Ivan Diaz-Padilla, Lisa Wang and Amit M. Oza

      Article first published online: 2 OCT 2014 | DOI: 10.1002/cncr.29030

      The anticipated clinical outcome of the standard/control arm is an important parameter in the design of randomized phase 3 trials for the accurate calculation of sample size, power, and study duration but is often underestimated in ovarian cancer trials. Changing patterns of care and variations in enrolled study populations may result in a deviation from the anticipated outcome and subsequent inaccurate statistical assumptions.

    2. Discipline

      Medical Oncology
      Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

      Liza C. Villaruz, Mark A. Socinski, Shira Abberbock, Lynne D. Berry, Bruce E. Johnson, David J. Kwiatkowski, A. John Iafrate, Marileila Varella-Garcia, Wilbur A. Franklin, D. Ross Camidge, Lecia V. Sequist, Eric B. Haura, Mark Ladanyi, Brenda F. Kurland, Kelly Kugler, John D. Minna, Paul A. Bunn and Mark G. Kris

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.29042

      The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. BRAF mutations occur in 2.2% of advanced-stage lung adenocarcinomas undergoing testing through the Lung Cancer Mutation Consortium, are most commonly V600E, and are associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas.

  37. Review Articles

    1. Therapeutic strategies for neuroendocrine liver metastases

      Andrea Frilling and Ashley K. Clift

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.28760

      Although multiple modalities are available for the treatment of neuroendocrine liver metastases, optimal management is unclear. The current knowledge pertaining to these treatment options is analyzed

  38. Correspondence

    1. Flawed assumptions used to defend screening mammography

      Archie Bleyer, Charles R. Thomas Jr, Cornelia Baines and Anthony B. Miller

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.29021

      Exaggerating the current benefit of screening mammography and minimizing its harms are readily accomplished by the application of assumptions based on data one-quarter to half of a century old, and they are neither reliable for predicting what is happening today nor appropriate for the treatment advances that have happened since. Helvie and colleagues are culpable of this conduct.

    2. Reply to flawed assumptions used to defend screening mammography

      Mark A. Helvie, Joanne T. Chang, R. Edward Hendrick and Mousumi Banerjee

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.29020

  39. Erratum

    1. You have free access to this content
  40. Review Articles

    1. Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

      Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

      Article first published online: 26 SEP 2014 | DOI: 10.1002/cncr.28935

      Bevacizumab provides benefit for patients with recurrent glioblastoma. The results of recent trials have indicated that its role among newly diagnosed patients remains unclear.

    2. Summing it up: An integrative review of studies of cancer survivorship care plans (2006-2013)

      Deborah K. Mayer, Sarah A. Birken, Devon K. Check and Ronald C. Chen

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.28884

      In this integrative review of the existing literature, the authors assess the state of scientific knowledge regarding survivorship care plans (SCPs). Studies regarding SCPs fall into 3 categories: 1) content, 2) dissemination and implementation, and 3) survivor and provider outcomes. The quantity and quality of research related to SCPs are limited.

  41. Original Articles

    1. Disease Site

      Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933

      Sylvia M. Lee, James Moon, Bruce G. Redman, Tarek Chidiac, Lawrence E. Flaherty, Yuanyuan Zha, Megan Othus, Antoni Ribas, Vernon K. Sondak, Thomas F. Gajewski and Kim A. Margolin

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29055

      This phase 2 trial investigates the safety and efficacy of RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with advanced melanoma and no prior systemic chemotherapy. RO4929097 is well tolerated but shows minimal clinical activity against metastatic melanoma, possibly in part because of a lack of adequate exposure of the tumor to therapeutic drug levels.

  42. Review Articles

    1. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

      Jayson I. L. Bastien, Katharine A. McNeill and Howard A. Fine

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.28968

      The last decade has seen an explosion of data elucidating the molecular and genetic drivers of glioblastoma, but clinical trials of molecularly targeted agents have been largely disappointing to date. This article reviews the most important genetic and epigenetic changes found in glioblastoma and the trials that have attempted to target those lesions, and it offers some potential reasons for their current lack of clinical efficacy.

  43. Original Articles

    1. Discipline

      Pediatric Oncology
      Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group

      Steven G. DuBois, Mark D. Krailo, Mark C. Gebhardt, Sarah S. Donaldson, Karen J. Marcus, John Dormans, Robert C. Shamberger, Scott Sailer, Richard W. Nicholas, John H. Healey, Nancy J. Tarbell, R. Lor Randall, Meenakshi Devidas, James S. Meyer, Linda Granowetter, Richard B. Womer, Mark Bernstein, Neyssa Marina and Holcombe E. Grier

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29065

      Patient characteristics differ according to the chosen mode of local control in Ewing sarcoma. Accounting for these differences, patients who are selected for definitive radiotherapy have higher rates of local failure but no differences in event-free or overall survival compared with patients who are selected for definitive surgery.

    2. Disease Site

      Gastrointestinal Disease
      Identification of novel mutations by exome sequencing in African American colorectal cancer patients

      Hassan Ashktorab, Mohammad Daremipouran, Joe Devaney, Sudhir Varma, Hamed Rahi, Edward Lee, Babak Shokrani, Russell Schwartz, Michael L. Nickerson and Hassan Brim

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.28922

      We have little knowledge of the phenotypic genetic changes of colorectal cancer in African Americans and their correlation with the DNA changes found in the majority of cancers in this population. Identifying biomarkers in colorectal cancer in African Americans is likely to help determine the key genes involved in the progression of this disease and identify biomarkers for targeted therapy and management in African Americans with colorectal cancer.

    3. Gynecologic Oncology
      Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

      Diana P. English, Stefania Bellone, Carlton L. Schwab, Dana M. Roque, Salvatore Lopez, Ileana Bortolomai, Emiliano Cocco, Elena Bonazzoli, Sudeshna Chatterjee, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford and Alessandro D. Santin

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29062

      Solitomab, a novel, bispecific, single-chain antibody, is highly active against chemotherapy-resistant epithelial ovarian carcinoma cell lines as well as unmanipulated malignant tumor cells in ascitic fluid. Solitomab may represent a novel, potentially highly effective, targeted agent for the treatment of chemotherapy-resistant ovarian disease that overexpresses epithelial cell adhesion molecule.

    4. Obesity is associated with worse quality of life in women with gynecologic malignancies: An opportunity to improve patient-centered outcomes

      Kemi M. Doll, Alison K. Kalinowski, Anna C. Snavely, Debra E. Irwin, Jeannette T Bensen, Victoria L. Bae-Jump, Kenneth H. Kim, Linda Van Le, Daniel L. Clarke-Pearson and Paola A. Gehrig

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29061

      Before cancer treatment, obese patients with gynecologic malignancies have worse baseline quality of life compared with their normal-weight counterparts. Emerging models of quality of life-based cancer outcome measures will significantly affect populations with a high obesity burden.

    5. Hematologic Malignancies
      Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study

      Jorge J. Castillo, Mark Bower, Jérémy Brühlmann, Urban Novak, Hansjakob Furrer, Paula Y. Tanaka, Caroline Besson, Silvia Montoto, Kate Cwynarski, Jeremy S. Abramson, Samir Dalia, Michele Bibas, Joseph M. Connors, Michael Furman, Minh-Ly Nguyen, Timothy P. Cooley, Brady E. Beltran, Jaime A. Collins, Julie M. Vose, Blanca Xicoy, Josep-Maria Ribera and for the HIV-Associated Hodgkin Lymphoma in the cART Era Study Group

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29066

      Based on results from this multicenter, retrospective study, the CD4-positive cell count at lymphoma diagnosis appears to be prognostic for progression-free and overall survival in patients with human immunodeficiency virus-associated, advanced-stage classical Hodgkin lymphoma who receive doxorubicin, bleomycin, vinblastine, and dacarbazine plus combination antiretroviral therapy. The patients who receive this treatment have excellent response and survival rates and should be treated akin to immunocompetent patients.

    6. Discipline

      Effectiveness of population-based service screening with mammography for women ages 40 to 49 years with a high or low risk of breast cancer: Socioeconomic status, parity, and age at birth of first child

      Barbro Numan Hellquist, Kamila Czene, Anna Hjälm, Lennarth Nyström and Håkan Jonsson

      Article first published online: 19 SEP 2014 | DOI: 10.1002/cncr.29011

      The invitation to mammography screening of women aged 40 to 49 years is an issue of debate in many countries and a cost-effective alternative in those countries without screening among these women could be inviting only those women at higher risk. For the 3 risk factors in the current study, the relative effectiveness for the high-risk groups was found to be the same as or higher than that of the low-risk groups, indicating that screening of high-risk groups (eg, nulliparous women) may be an alternative.

    7. Radiation Oncology
      Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer patients undergoing definitive radiation therapy: Pilot study results

      Jay F. Dorsey, Gary D. Kao, Kelly M. MacArthur, Melody Ju, David Steinmetz, E. Paul Wileyto, Charles B. Simone II and Stephen M. Hahn

      Article first published online: 19 SEP 2014 | DOI: 10.1002/cncr.28975

  44. Review Articles

    1. Psychiatric implications of cancer genetic testing

      April Malia Hirschberg, Gayun Chan-Smutko and William F. Pirl

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.28879

      Cancer genetic testing itself does not appear to cause significant psychological or psychiatric issues, although individuals who present for testing may have baseline psychosocial issues or risk factors that must be addressed during the testing process. Psychiatric predictors of cancer genetic testing, the psychosocial impact of testing, risk perception and adherence to recommendations for risk reduction of identified hereditary cancer syndromes, and recommendations for mental health interventions are reviewed.

  45. Original Articles

    1. Disease Site

      Breast Disease
      Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico

      Cynthia Villarreal-Garza, Rosa María Alvarez-Gómez, Carlos Pérez-Plasencia, Luis A. Herrera, Josef Herzog, Danielle Castillo, Alejandro Mohar, Clementina Castro, Lenny N. Gallardo, Dolores Gallardo, Miguel Santibáñez, Kathleen R. Blazer and Jeffrey N. Weitzel

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.29058

      This is the first study of BRCA mutation prevalence among unselected breast cancer and ovarian cancer cases in Mexico, demonstrating a remarkably high frequency of BRCA mutations, including a high percentage with the Mexican founder mutation, BRCA1 ex9-12del. The HISPANEL, an economic and sensitive tool that detects recurrent BRCA mutations, has the potential to provide cost-effective cancer prevention and management by improving access to genetic cancer risk assessment among underserved populations like Mexico.

    2. Discipline

      Supportive Care
      Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

      Ole-Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin, Rana R. McKay, Lipika Goyal, Michael Davis, Marina D. Kaymakcalan and Jonathan S. Williams

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.28972

      Older age, higher body mass index, and preexisting hypertension are risk factors for the development of a treatment-induced hypertensive response to VEGF signaling pathway inhibitors. The development of hypertension was associated with improved survival.

  46. Review Articles

    1. Quo vadis: Advanced prostate cancer—clinical care and clinical research in the era of multiple androgen receptor-directed therapies

      Won Kim and Charles J. Ryan

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.28929

      Despite advances in novel androgen receptor-directed therapies that have changed the landscape of advanced prostate cancer treatment, many critical questions remain unanswered, and obstacles remain in optimizing the care for patients burdened with the disease.

  47. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: Results from a population-based study

      Sachin Wani, Ananya Das, Amit Rastogi, Jennifer Drahos, Winifred Ricker, Ruth Parsons, Ajay Bansal, Roy Yen, Lindsay Hosford, Meghan Jankowski, Prateek Sharma and Michael B. Cook

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.29043

      Patients undergoing endoscopic ultrasound (EUS), computed tomography (CT)–positron emission tomography (PET), or EUS and CT-PET have improved survival at all stages (with the exception of stage 0 disease) in comparison with patients undergoing no EUS or CT-PET. Receipt of EUS is a significant predictor for improved 1-, 3-, and 5-year survival. Similar results are noted when the results are stratified on the basis of histology and for groups undergoing CT-PET or EUS plus CT-PET.

    2. Gynecologic Oncology
      Polymerase ɛ (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing

      Caroline C. Billingsley, David E. Cohn, David G. Mutch, Julie A. Stephens, Adrian A. Suarez and Paul J. Goodfellow

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29046

      Mutation in the polymerase ɛ gene (POLE) exonuclease domain is a defining feature of a subgroup of endometrial cancers (ECs) with very high somatic mutation burden and for which improved progression-free survival has been reported; however, in this analysis of 544 ECs, no significant survival association is identified, indicating that POLE mutation is unlikely to be a clinically applicable prognostic marker. However, some high rates of POLE defects in a subset of microsatellite unstable cancers appear to be associated with somatic mutation in DNA mismatch repair genes, a finding with important implications for Lynch syndrome testing in patients with EC.

  48. Editorials

    1. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for Lynch syndrome testing

      Panagiotis A. Konstantinopoulos and Ursula A. Matulonis

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29057

      In endometrial cancer, the presence of polymerase ɛ (POLE) exonuclease domain mutations in immunohistochemically abnormal/microsatellite unstable/mutL homolog1-unmethylated tumors may serve as a marker of somatic origin. These mutations may be important in making determinations and recommendations for mismatch repair gene mutation testing in women with endometrial cancer.

  49. Original Articles

    1. Discipline

      Medical Oncology
      Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

      Jacqueline Mersch, Michelle A. Jackson, Minjeong Park, Denise Nebgen, Susan K. Peterson, Claire Singletary, Banu K. Arun and Jennifer K. Litton

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29041

      In a cohort of more than 1000 known mutation carriers, BRCA2 mutations are associated with a higher rate of pancreatic cancer than previously reported. Increases have also been observed in prostate cancer and melanoma.

    2. Pediatric Oncology
      Parent decision-making around the genetic testing of children for germline TP53 mutations

      Melissa A. Alderfer, Kristin Zelley, Robert B. Lindell, Ana Novokmet, Phuong L. Mai, Judy E. Garber, Deepika Nathan, Sarah Scollon, Nicolette M. Chun, Andrea F. Patenaude, James M. Ford, Sharon E. Plon, Joshua D. Schiffman, Lisa R. Diller, Sharon A. Savage, David Malkin, Carol A. Ford and Kim E. Nichols

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29027

      Li-Fraumeni Syndrome (LFS) is a rare genetic cancer predisposition syndrome caused by germline TP53 mutations in which up to 20% of mutation carriers develop cancer during childhood. Although empirical evidence regarding benefits and risks of TP53 testing during childhood are lacking, most parents in our study decided easily in favor of testing and perceived a range of advantages that outweighed risks.

    3. Medical Oncology
      Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea

      Yoon Young Cho, Jiwon Lim, Chang-Mo Oh, Junsun Ryu, Kyu-Won Jung, Jae Hoon Chung, Young-Joo Won and Sun Wook Kim

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29025

      In patients with primary thyroid cancer, the risks of several cancers are elevated significantly during follow-up. Thus, physicians are needed to pay special attention in their care of thyroid cancer patients and long-term survivors.


  1. 1 - 100
  2. 101 - 156